Oncocyte Corporation Forecast, price target & analysts
Oncocyte Corporation Target price 2025 - Analyst rating & recommendation
Oncocyte Corporation Classifications & Recommendation:
Oncocyte Corporation Price Target
| Target Price | $4.42 |
| Price | $2.95 |
| Potential |
49.72%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Oncocyte Corporation 2026 .
The average Oncocyte Corporation target price is $4.42.
This is
49.72%
register free of charge
$5.00
69.49%
register free of charge
$4.00
35.59%
register free of charge
|
|
| A rating was issued by 4 analysts: 2 Analysts recommend Oncocyte Corporation to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Oncocyte Corporation stock has an average upside potential 2026 of
49.72%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.88 | 1.03 |
| 25.33% | 45.48% | |
| EBITDA Margin | -1,153.19% | -2,448.78% |
| 15.99% | 112.35% | |
| Net Margin | -4,325.37% | -1,821.61% |
| 0.85% | 57.89% |
4 Analysts have issued a sales forecast Oncocyte Corporation 2025 . The average Oncocyte Corporation sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Oncocyte Corporation 2025 . The average Oncocyte Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Oncocyte Corporation Analysts have issued a net profit forecast 2025. The average Oncocyte Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.66 | -1.07 |
| 24.27% | 77.04% | |
| P/E | negative | |
| EV/Sales | 78.85 |
4 Analysts have issued a Oncocyte Corporation forecast for earnings per share. The average Oncocyte Corporation EPS is
This results in the following potential growth metrics and future valuations:
Oncocyte Corporation...
Current Oncocyte Corporation Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Lake Street |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Nov 13 2024 |
| Needham |
Locked
➜
Locked
|
Locked | Oct 15 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Lake Street:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 26 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Mar 25 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Mar 25 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Nov 13 2024 |
|
Locked
Needham:
Locked
➜
Locked
|
Oct 15 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
